N※N

Merck Acquires Terns for $1.5B, Boosting CML Treatment Portfolio

  //stocks-investing.news-articles.net/content/202 .. s-for-1-5b-boosting-cml-treatment-portfolio.html
  Published in Stocks and Investing on Wednesday, March 25th 2026 at 18:56 GMT by Seeking Alpha
      Locales: UNITED STATES, SWITZERLAND

Wednesday, March 25th, 2026 - Merck (MRK) has solidified its position as a leader in oncology with the completion of its acquisition of Terns Pharmaceuticals, a deal initially announced in early 2026. The transaction, valued at $1.5 billion upfront with potential for up to $3.5 billion in milestone payments, centers around Terns' promising drug candidate, TBR-0812, a novel treatment for Chronic Myeloid Leukemia (CML). This move signals not only Merck's confidence in TBR-0812's potential but also the evolving landscape of CML treatment and the growing need for next-generation therapies.

For over two decades, Novartis's Gleevec (imatinib) revolutionized CML treatment, transforming a once-fatal disease into a manageable chronic condition. However, the reality is that many patients eventually develop resistance to first-generation tyrosine kinase inhibitors (TKIs) like Gleevec. This resistance stems from mutations in the BCR-ABL1 gene, the driver of CML, rendering the initial treatment ineffective. While second and third-generation TKIs have emerged, addressing some resistance mutations, a significant unmet need persists for patients who have progressed through multiple lines of therapy. This is where TBR-0812, now a key asset within Merck's oncology portfolio, steps in.

TBR-0812 stands out as a highly selective TKI designed to potently inhibit the BCR-ABL1 kinase, even in the face of mutations that cause resistance to older TKIs. Early clinical data, released prior to the acquisition, demonstrated promising results in patients with CML who had failed multiple prior treatments, showcasing a robust response rate and encouraging safety profile. Unlike broader-spectrum TKIs, TBR-0812's selectivity aims to minimize off-target effects, potentially reducing the incidence of adverse events and improving patient quality of life.

The CML treatment market is currently dominated by established players like Novartis (with their subsequent generations of TKIs), Incyte (with Jakafi, primarily used for myelofibrosis but also gaining traction in CML), and Pfizer (with Xeljanz, an oral JAK inhibitor). Competition is fierce, but analysts believe TBR-0812's unique mechanism of action and potential to overcome resistance gives it a strong position to capture a significant share of the refractory CML patient population. The anticipated peak sales for TBR-0812 are estimated to be in the $2-3 billion range, justifying Merck's substantial investment.

What Does This Mean for Patients?

The acquisition of Terns and the development of TBR-0812 offer hope to patients who have exhausted current treatment options. The drug represents a potential fourth-line therapy, offering a lifeline for those who have become resistant to all available TKIs. The increased selectivity promises to minimize side effects that are often debilitating for patients undergoing long-term treatment. Merck's robust resources and expertise in drug development are expected to accelerate the clinical trial process and potentially bring TBR-0812 to market faster.

The Financial Implications and Merck's Strategy

While the initial $1.5 billion upfront payment is considerable, analysts largely agree that Merck paid a reasonable price, especially considering the potential peak revenue and the critical unmet need in the CML space. The milestone payments, tied to regulatory approvals and commercial success, provide a performance-based incentive for Terns' team and mitigate Merck's risk. This deal aligns with Merck's broader strategy of focusing on innovative oncology therapies and expanding its portfolio of precision medicines. The company has made several strategic acquisitions in recent years, targeting companies with promising drug candidates in areas like lung cancer, melanoma, and now, CML.

Furthermore, this acquisition allows Merck to diversify its revenue streams beyond its established blockbuster drugs. As patents on older medications expire, pharmaceutical companies are increasingly reliant on new product launches to maintain profitability. TBR-0812 offers a long-term growth opportunity for Merck, securing its position at the forefront of cancer treatment innovation. The company is expected to integrate TBR-0812 into its existing oncology infrastructure, leveraging its expertise in clinical trials, manufacturing, and commercialization to maximize the drug's potential. The final FDA approval of TBR-0812 is anticipated in late 2027 or early 2028, marking a new era in the treatment of CML.